{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-011598","form_type":"8-K","ticker":"SRTS","cik":"0001494891","company_name":"Sensus Healthcare, Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.329915+00:00","generated_at":"2026-06-06T05:35:30.754087+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sensus Healthcare Q4 revenue $12.6M, net income $4.2M; introduces recurring revenue model","bullets":["Q4 revenue $12.6M (vs $13.1M YoY) but up 3x sequentially from Q3 $3.9M; net income $4.2M ($0.26 diluted EPS) vs $2.8M YoY.","Full-year 2023 net income positive at $0.03 diluted EPS; shipped 66 SRT units (33 in Q4). Cash $23.1M, no debt.","Introduced recurring revenue model for SRT-100 Vision; first placement completed with multiple in pipeline.","Appointed President & General Counsel Michael Sardano to Board of Directors.","Engaged CureRays for clinical oversight and studies to expand SRT indications beyond skin cancer and keloids."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-011598","json":"https://secwatch.observer/filing/0001213900-24-011598.json","markdown":"https://secwatch.observer/filing/0001213900-24-011598.md","text":"https://secwatch.observer/filing/0001213900-24-011598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1494891/000121390024011598/0001213900-24-011598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1494891/000121390024011598/ea193048-8k_sensus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:35:30.754087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"589ae780d0db42f6e4815fd385b2371257a73ad9","claim":"Sensus Healthcare, Inc. reported the quarter and year ended December 31, 2023 results: revenue $12.6 million, net income $4.2 million, EPS $0.26 per diluted share.","evidence_excerpt":"PRESS RELEASE, DATED FEBRUARY 8, 2024 Exhibit 99.1 Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results ● Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditions ● Introduces recurring revenue model for the SRT-100 VisionTM (IG-SRT) to address","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1494891/000121390024011598/0001213900-24-011598-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$12.6 million"},{"label":"Net income","value":"$4.2 million"},{"label":"EPS","value":"$0.26 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}